The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Cardioprotective interventions for cancer patients receiving anthracyclines
Open accessAbstract
BACKGROUND: Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. Unfortunately, their use is limited by a dose-dependent cardiotoxicity. In an effort to prevent this cardiotoxicity, different cardioprotective agents have been studied. OBJECTIVES: The objective of this review was to assess the efficacy of different cardioprotective agents in preventing heart damage in cancer patients treated with anthracyclines. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE (1966 to November 2010) and EMBASE (1980 to November 2010) databases. In addition, we handsearched reference lists, conference proceedings of the International Society of Paediatric Oncology (SIOP) and American Society of Clinical Oncology (ASCO) meetings (1998 to 2010) and ongoing trials registers. SELECTION CRITERIA: Randomised controlled trials (RCTs) in which any cardioprotective agent was compared to no additional therapy or placebo in cancer patients (children and adults) receiving anthracyclines. DATA COLLECTION AND ANALYSIS: Two review authors independently performed the study selection, risk of bias assessment and data extraction including adverse effects. MAIN RESULTS: We identified RCTs for the eight cardioprotective agents N-acetylcysteine, phenethylamines, coenzyme Q10, a combination of vitamins E and C and N-acetylcysteine, L-carnitine, carvedilol, amifostine and dexrazoxane (mostly for adults with advanced breast cancer). All studies had methodological limitations and for the first seven agents there were too few studies to allow pooling of results. None of the individual studies showed a cardioprotective effect. The 10 included studies on dexrazoxane enrolled 1619 patients. The meta-analysis for dexrazoxane showed a statistically significant benefit in favour of dexrazoxane for the occurrence of heart failure (risk ratio (RR) 0.29, 95% CI 0.20 to 0.41). No evidence was found for a difference in response rate or survival between the dexrazoxane and control groups. The results for adverse effects were ambiguous. No significant difference in the occurrence of secondary malignancies was identified. AUTHORS' CONCLUSIONS: No definitive conclusions can be made about the efficacy of cardioprotective agents for which pooling of results was impossible. Dexrazoxane prevents heart damage and no evidence for a difference in response rate or survival between the dexrazoxane and control groups was identified. The evidence available did not allow us to reach any definite conclusions about adverse effects. We conclude that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines. However, clinicians should weigh the cardioprotective effect of dexrazoxane against the possible risk of adverse effects for each individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Moghrabi, A., Levy, D. E., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Samson, Y., Schorin, M., Dalton, V. K., Lipshultz, S. E., et al. (2007) · Blood · doi:10.1182/blood-2006-06-027714 · Cited by 403
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf167 · Cited by 354
Self-citationCARDIAC TOXICITY OF DAUNORUBICIN
Bonadonna, G., Monfardini, S., Marmont, A., Damasio, E., & Rossi, F. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92093-5 · Cited by 348
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Biomedical and clinical aspects of coenzyme Q
Littarru, G. P. (1993) · The Clinical Investigator · doi:10.1007/bf00184478 · Cited by 310
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Self-citationKremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Self-citationSalzer, W. L., Devidas, M., Carroll, W. L., Winick, N., Pullen, J., Hunger, S. P., & Camitta, B. A. (2010) · Leukemia · doi:10.1038/leu.2009.261 · Cited by 235
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Schwartz, C. L., Constine, L. S., Villaluna, D., London, W. B., Hutchison, R. E., Sposto, R., Lipshultz, S. E., Turner, C. S., deAlarcon, P. A., & Chauvenet, A. R. (2009) · Blood · doi:10.1182/blood-2008-10-184143 · Cited by 212
Marty, M., Espié, M., Llombart, A., Monnier, A., Rapoport, B. L., & Stahalova, V. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj134 · Cited by 202
Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome
van Woerden, C. S. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/18.2.273 · Cited by 180
The role of iron in doxorubicin-induced cardiomyopathy.
Myers, C. (1998) · PubMed · Cited by 168
Venturini, M., Michelotti, A., Del Mastro, L., Gallo, L., Carnino, F., Garrone, O., Tibaldi, C., Molea, N., Bellina, R. C., Pronzato, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.12.3112 · Cited by 165
Cadeddu, C., Piras, A., Mantovani, G., Deidda, M., Dessì, M., Madeddu, C., Massa, E., & Mercuro, G. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.05.037 · Cited by 159
Cascinu, S., Cordella, L., Ferro, E. D., Fronzoni, M., & Catalano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.26 · Cited by 158
van Dalen, E. C., van der Pal, H. J. H., Caron, H. N., & Kremer, L. C. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005008.pub3 · Cited by 145
Self-citationLópez, M., Vici, P., Lauro, K. D., Conti, F., Paoletti, G., Ferraironi, A., Sciuto, R., Giannarelli, D., & MAINI, C. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.86 · Cited by 140
Cochat, P. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00477.x · Cited by 138
Combination therapy with probucol prevents adriamycin-induced cardiomyopathy
Singal, P. K. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(95)90074-8 · Cited by 131
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2481 · Cited by 118
Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., & Iacono, A. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90030-2 · Cited by 114
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub3 · Cited by 113
Self-citationMotley, A. M., Lumb, M. J., Oatey, P. B., Jennings, P. R., de Zoysa, P. A., Wanders, R. J. A., Tabak, H. F., & Danpure, C. J. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.1.95 · Cited by 91
Interstitial cells of Cajal are involved in the afferent limb of the rectoanal inhibitory reflex
de Lorijn, F., de Jonge, W., Wedel, T., Vanderwinden, J., Benninga, M., & Boeckxstaens, G. (2005) · Gut · doi:10.1136/gut.2004.051045 · Cited by 87
van Acker, F. A. A., van Acker, S. A. B. E., Kramer, K., Haenen, G. R. M. M., Bast, A., & van der Vijgh, W. J. F. (2000) · PubMed · Cited by 73
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub3 · Cited by 72
Self-citationAGXT Gene Mutations and Their Influence on Clinical Heterogeneity of Type 1 Primary Hyperoxaluria
Amoroso, A., Pirulli, D., Florian, F., Puzzer, D., Boniotto, M., Crovella, S., Zezlina, S., Spanò, A., Mazzola, G. A., Savoldi, S., et al. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102072 · Cited by 56
Elihu, N., Anandasbapathy, S., & Frishman, W. H. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04397.x · Cited by 52
Waldner, R., Laschan, C., Lohninger, A., Gessner, M., Tüchler, H., Huemer, M., Spiegel, W., & Karlic, H. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0054-8 · Cited by 41
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J. R., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowsky, M., et al. (2001) · American Heart Journal · doi:10.1067/mhj.2001.118115 · Cited by 39
N-acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP.
Unverferth, D. V., Fertel, R. H., Balcerzak, S. P., et al. (1983) · PubMed · Cited by 12
T�chler, H., Hofmann, S., Bernhart, M., Brugiatelli, M., Chrobák, L., Franke, A., Herold, M., Hołowiecki, J., Ihle, R., Jaksic, B. S., et al. (1992) · Quality of Life Research · doi:10.1007/bf00439718 · Cited by 11
Research works printed but not linked: 49
- Galetta, 2005, Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients, Biomedicine & Pharmacotherapy, 59, 541, 10.1016/j.biopha.2004.12.003 · DOI
- Gallegos-Castorena, 2007, Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin, Pediatric Hematology and Oncology, 24, 403, 10.1080/08880010701451244 · doi:10.1080/08880010701451244
- Kraft, 1990, Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial, Haematology and Blood Transfusion, 33, 566, 10.1007/978-3-642-74643-7_103 · doi:10.1007/978-3-642-74643-7_103
- Milei, 1987, Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study, Cancer Drug Delivery, 4, 129, 10.1089/cdd.1987.4.129 · doi:10.1089/cdd.1987.4.129
- Myers, 1983, A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine, Seminars in Oncology, 10 Suppl 1, 53
- Swain, 1997, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, Journal of Clinical Oncology, 15, 1318, 10.1200/JCO.1997.15.4.1318 · DOI · Paper page
- Wagdi, 1995, Cardioprotection during chemo-and radiotherapy of malignant diseases - an echocardiographic pilot study, Schweizerische Rundschau fur Medizin (Praxis), 84, 1220
- Bates, 1997, A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer, Clinical Therapeutics, 19, 167, 10.1016/S0149-2918(97)80084-7 · DOI
- Batist, 1985, Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition, Cancer Research, 45, 5900
- Judy, 1984, Coenzyme Q10 reduction of adriamycin cardiotoxicity, 4, 231
- Massidda, 1997, Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study, Anticancer Research, 17, 663
- Michelotti, 2000, Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients, Breast Cancer Research and Treatment, 59, 133, 10.1023/A:1006394801389 · doi:10.1023/a:1006394801389
- Nakamae, 2005, Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, Cancer, 104, 2492, 10.1002/cncr.21478 · doi:10.1002/cncr.21478
- Neto, 2006, Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane, Arquivos Brasileiros de Cardiologia, 87, 699
- Paiva, 2005, Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography, Pediatric Blood and Cancer, 45, 902, 10.1002/pbc.20488 · DOI · Paper page
- Piccinini, 1987, Protective effect of trimetazidine on the cardiotoxicity of doxorubicin, Concours Medical, 109, 3479
- Rosenfeld, 1992, Prevention of adriamycin cardiomyopathy with dexrazoxane (ADR-529, ICRF-187), Proceedings of ASCO, 11, 62
- Speyer, 1990, A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer, Cancer Treatment Reviews, 17, 161, 10.1016/0305-7372(90)90041-D · doi:10.1016/0305-7372(90)90041-d
- Tallarico, 2003, Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy, Angiology, 54, 219, 10.1177/000331970305400212 · doi:10.1177/000331970305400212
- Bokkel-Huinink, 1990, ICRF 187 protects against doxorubicin induced cardiomyopathy, Annals of Oncology, 1, 106
- Tonkin, 1996, Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation, Annals of Cancer Control Research, 6, 458
- Unverferth, 1983, Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine, Journal of the National Cancer Institute, 71, 917
- Vici, 1998, Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment, La Clinica Terapeutica, 149, 15
- Wagdi, 1996, Cardioprotection in patients undergoing chemo-and/or radiotherapy for neoplastic disease: a pilot study, Japanese Heart Journal, 37, 353, 10.1536/ihj.37.353 · doi:10.1536/ihj.37.353
- Weisberg, 1992, Dexrazoxane (ADR-529, ICRF-187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity, Proceedings of ASCO, 11, 91
- Weitzman, 1980, Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity, Current Therapeutic Research, 28, 682
- Whittaker, 1984, Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia, British Medical Journal, 288, 283, 10.1136/bmj.288.6413.283-a · doi:10.1136/bmj.288.6413.283-a
- Whittaker, 1987, Doxorubicin cardiotoxicity: attempts at prevention with digoxin and alpha-tocopherol (vitamin E), Clinical Trials Journal, 24 Suppl 1, 45
- Cardenas, 2003, Effectiveness and safety of dexrazoxane as a cardioprotector in Mexican children with cancer, Medical and Pediatric Oncology, 41, PL001
- De Berranger E Results of randomized study on dexrazoxane administration in children with de novo acute leukemia ASCO Annual Meeting (abstract number 9037) 2006 · doi:10.1200/jco.2006.24.18_suppl.9037
- Gu, 2010, Clinical observation of hydroprednisone and glutathione in chemotherapy of breast cancer, Chinese Journal of Cancer Prevention and Treatment, 17, 131
- Jackowska, 2003, Assessment of dexrazoxane tolerance in leukemic children receiving anthracyclines, Medical and Pediatric Oncology, 41, PD003
- Saad El-Din, 2003, A randomized clinical trial to evaluate cardioprotective effect of ICRF-187 in children with acute lymphoblastic leukemia, Medical and Pediatric Oncology, 41, O109
- Bokkel-Huinink, 1992, ICRF 187 protects against doxorubicin induced cardiomyopathy, Annals of Oncology (abstract number 221), 114
- Barry, 2008, Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane, Journal of Clinical Oncology, 26, 1106, 10.1200/JCO.2007.12.2481 · DOI
- Leonardis, 1985, Reduction of cardiac toxicity of anthracyclines by L-Carnitine: preliminary overview of clinical data, International Journal of Clinical Pharmacology Research, 5, 137
- Garbrecht, 1986, Verapamil in the prevention of adriamycin-induced cardiomyopathy, Klinische Wochenschrift, 64 Suppl VII, 132
- Guthrie, 1977, Doxorubicin cardiotoxicity: possible role of digoxin in its prevention, British Medical Journal, 2, 1447, 10.1136/bmj.2.6100.1447 · doi:10.1136/bmj.2.6100.1447
- Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated September 2006] John Wiley & Sons, Ltd
- Hofmann, 1993, A questionnaire suitable for general practice for detection of the health status and quality of life of patients with hemato-oncologic diseases: psychometric properties. The study G "quality of life" of the International Society for Chemo-and Immunotherapy (I.G.C.I.), Wiener Klinische Wochenschrift, 105, 277
- Kawasaki, 1992, Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C, Japanese Journal of Cancer Research, 83, 899, 10.1111/j.1349-7006.1992.tb01997.x · doi:10.1111/j.1349-7006.1992.tb01997.x
- Legha, 1982, Clinical and pharmacologic investigation of the effects of a-tocopherol on adriamycin cardiotoxicity, Annals of the New York Academy of Sciences, 393, 411, 10.1111/j.1749-6632.1982.tb31279.x · doi:10.1111/j.1749-6632.1982.tb31279.x
- Lipshultz, 1998, 48 hour continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later: the DFCI 91001 ALL protocol, Proceedings of the American Society of Clinical Oncology, 17, 528a
- Lipshultz, 2010, Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, Lancet Oncology, 11, 950, 10.1016/S1470-2045(10)70204-7 · DOI · Paper page
- Muggia, 1991, New anthracycline antitumor antibiotics, Critical Reviews in Oncology/Hematology, 11, 43, 10.1016/1040-8428(91)90017-7 · doi:10.1016/1040-8428(91)90017-7
- Odaimi, 1987, High-dose chemotherapy, American Journal of Clinical Oncology, 10, 123, 10.1097/00000421-198704000-00045 · doi:10.1097/00000421-198704000-00045
- Pierga, 2001, Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, Annals of Oncology, 12, 231, 10.1023/A:1008330527188 · doi:10.1023/a:1008330527188
- Dalen, 2011, Should anthracyclines and dexrazoxane be used for children with cancer?, Lancet Oncology, 12, 12, 10.1016/S1470-2045(10)70301-6 · doi:10.1016/s1470-2045(10)70301-6
- Dalen, 2008, Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003917.pub3 · DOI
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Metadata
- Authors
- van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2011-06-15
- Volume
- 2016
- Issue
- 9
- Pages
- CD003917-CD003917
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2150475243
- Cited by
- 553
- References
- 55
- FWCI
- 26.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.